Sinovac Biotech Ltd.
SVA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $644,461 | $643,780 | $642,546 | $639,866 |
| - Cash | $1,270,131 | $4,278,124 | $11,608,855 | $1,041,008 |
| + Debt | $298,983 | $74,673 | $144,907 | $136,386 |
| Enterprise Value | -$326,687 | -$3,559,671 | -$10,821,402 | -$264,756 |
| Revenue | $448,269 | $1,492,761 | $19,374,904 | $510,624 |
| % Growth | -70% | -92.3% | 3,694.4% | – |
| Gross Profit | $266,753 | $808,305 | $18,302,683 | $443,444 |
| % Margin | 59.5% | 54.1% | 94.5% | 86.8% |
| EBITDA | -$6,029 | $183,099 | $17,652,709 | $221,763 |
| % Margin | -1.3% | 12.3% | 91.1% | 43.4% |
| Net Income | -$99,918 | $113,866 | $8,467,480 | $110,369 |
| % Margin | -22.3% | 7.6% | 43.7% | 21.6% |
| EPS Diluted | -1.06 | 1 | 74.27 | 0.97 |
| % Growth | -206% | -98.7% | 7,556.7% | – |
| Operating Cash Flow | $103,997 | -$770,745 | $15,352,541 | $479,309 |
| Capital Expenditures | -$145,688 | -$403,368 | -$719,977 | -$127,650 |
| Free Cash Flow | -$41,691 | -$1,174,113 | $14,632,564 | $351,659 |